Loading clinical trials...

Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy

Efficacy and Safety of Astragalus for Non-Motor Symptoms of α-Synucleinopathy：an Open-Label Self-Controlled Before-and-After Study

NCT05506891•Fujian Medical University Union Hospital

View on ClinicalTrials.gov

Summary

α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. However, there is still a lack of research on the treatment for non-motor symptoms of α-synucleinopathy, especially autonomic dysfunctions such as orthostatic hypotension. Efficacy and safety of astragalus for non-motor symptoms of α-synucleinopathy will be assessed by an open-label self-controlled before-and-after study.

Eligibility

Age

30 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants with a clinical diagnosis of PD, MSA and DLB, with orthostatic hypotension.
•Participants with cognitive disorder.
•Adults signed informed consents.

Exclusion Criteria

•Patients with history of astragalus allergy.
•Patients with secondary Parkinsonism that cannot be excluded.
•Patients with diseases that may cause other types of hypotension or similar symptoms/signs because of hypotension
•Patients with other medical conditions requiring treatments that may affect blood pressure.
•Patients with other neurological disorders.
•Patients with serious comorbidities and immune diseases.
•Uncooperative patients.
•Pregnant or lactating women.

Locations (1)

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Key Dates

Start Date

October 1, 2023

Primary Completion Date

July 1, 2024

Completion Date

July 1, 2024

Last Updated

September 13, 2023

Enrollment

ESTIMATED participants

Conditions

Parkinsonism

Interventions

Physical therapy group

BEHAVIORAL

Astragalus

DRUG

Contacts

Xiaodong Pan

CONTACT

0591-86218341 pxd77316@163.com

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients

NCT07442370

Parkinson DiseaseParkinsonism

View study

RECRUITINGNA

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

NCT07056361

Movement Disorders (Incl Parkinsonism)Stroke+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 13, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy

Inclusion Criteria

Exclusion Criteria

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.

Aim 3 Particle Swarm Optimization PIGD

Proteinopathies Expression in Skin of Neurodegenerative Disorders

The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders